Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Registration       Hotel       Presenter Instructions       Late Breaking       Support & Exhibits     2014 Overview       Program       Travel & Transportation      

Schedule at a Glance
 
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Daily Schedule - Thursday, December 11, 2014

 
Tuesday | Wednesday | Thursday | Friday | Saturday
THURSDAY, DECEMBER 11, 2014
     
7:00 am - 5:15 pm Registration - Bridge Hall  
     
7:30 am - 9:00 am

POSTER SESSION 2 & continental breakfast - Exhibit Halls A-B

 
     
 

Detection and Diagnosis

 
 

Axillary Staging and Sentinel Nodes

Biopsy Techniques

P2-01

P2-02

 

Tumor Cell and Molecular Biology

 
 

Genomics

Tumor Heterogeneity/Molecular Subclassification

Molecular Profiles

Stem/Progenitor Cells

Epithelial-Mesenchymal Transition

Etiology/Carcinogenesis

P2-03

P2-04

P2-05

P2-06

P2-07

P2-08

  Psychosocial, Quality of Life, and Educational Aspects  
 

Advocacy

Doctor-Patient Communication

Education

Psychosocial, QOL, and Educational Aspects - Other

P2-09

P2-10

P2-11

P2-12

  Treatment  
 

Surgery

Reconstruction

Immunotherapy (Clinical

Antibody-Based Regimens

Antiangiogenic Therapy (Adjuvant and Metastatic)

Treatment - Other

P2-13

P2-14

P2-15

P2-16

P2-17

P2-18

     
9:00 am - 9:30 am PLENARY LECTURE 2 – Exhibit Hall D  
 

Patient Derived Xenografts - Pre-Clinical Models for Prevention and Treatment of Metastasis

Alana L. Welm, PhD
Oklahoma Medical Research Foundation

Oklahoma City, OK

 
     
9:30 am - 12:00 pm

GENERAL SESSION 3 – Exhibit Hall D

 
     
9:30 am

S3-01. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S, Abraham J, Barrett S, Barrett-Lee P, Chan S, Cheang M, Fox L, Grigoriadis A, Harper-Wynne C, Hatton M, Kernaghan S, Owen J, Parker P, Rahman N, Roylance R, Smith I, Thompson R, Tovey H, Wardley A, Wilson G, Harries M, Bliss J.  Kings College London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU), London, United Kingdom; Velindre NHS Trust Cancer Centre, Cardiff, United Kingdom; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Cancer Research UK London Research Institute, London, United Kingdom; The Institute of Cancer Research, London, United Kingdom; Barts Health NHS Trust, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom; BME Cancer Communities, Nottingham, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom.

 
     
9:45 am

S3-02. NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer
Samuel JA, Wilson JW, Bandos H, Elledge RM, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, Brufsky AM, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Rastogi P, Julian TB, Wickerham DL, Swain SM, Geyer, Jr CE, Mamounas EP, Wolmark N.  National Surgical Adjuvant Breast and Bowel Project (NSABP); University of Pittsburgh Medical Center; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh; Baylor College of Medicine, Houston; Centre Hospitalier de l'Université de Montréal (CHUM), Canada; Kaiser Permenente, Northern California, Vallejo; Onoclogy/Hematology Care Clinical Trials; Kaiser Permanente, San Diego; University of Pittsburgh Cancer Institute; Centre Hospitalier Affilie Universitaire de Quebec (CHA), Canada; Tom Baker Cancer Centre, Canada; Norton Cancer Institute; CCOP, Ozark Health Ventures LLC-Cancer Research for the Ozarks; MBCCOP, San Juan; Allegheny Cancer Center at Allegheny General Hospital; Washington Cancer Institute Medstar Washington Hospital; Virginia Commonwealth University, Massey Cancer Center; UF Cancer Center at Orlando Health.

 
     
10:00 am

S3-03. Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer
Sparano JA, Zhao F, Martino S, Ligibel J, Saphner T, Wolff AC, Sledge, Jr GW, Perez EA, Wood WC, Davidson NE.  Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Dana Farber Cancer Institute, Boston, MA; The Angeles Clinic, Los Angeles, CA; Aurora Health, Two Rivers, WI; Johns Hopkins, Baltimore, MD; Stanford University, Stanford, CA; Mayo Clinic; Emory University, Atlanta, GA; University of Pittsburgh, Pittsburgh, PA.

 
     
10:15 am

S3-04. The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer
von Minckwitz G, Reimer T, Potenberg J, Conrad B, Sch[uuml]rer U, Eidtmann H, Just M, Paepke S, Stickeler E, Heinrich G, Untch M, Moebus V, Thomssen C, Jackisch C, Huober J, Loibl S, Nekljudova V, Nitz U.  German Breast Group, Neu-Isenburg; Universitäts-Frauenklinik, Frankfurt am Main; Klinikum Südstadt, Universitäts-Frauenklinik, Rostock; Evangelisches Waldkrankenhaus, Berlin; Elisabeth Krankenhaus, Kassel; Klinikum Meiningen GmbH, Meiningen; Universitätsklinikum Schleswig-Holstein, Kiel; Onkologische Schwerpunktpraxis, Bielefeld; Universitäts-Frauenklinik rechts der Isar, München; Universitäts-Frauenklinik Freiburg; Onkologische Schwerpunktpraxis, Fürstenwalde; Helios Klinikum Berlin-Buch; Städtische Kliniken Hoechst, Frankfurt; Universitäts-Frauenklinik Halle; Frauenklinik Sana-Klinikum Offenbach; Universitäts-Frauenklinik Ulm; Bethesda Klinikum Moenchengladbach.

 
     
10:30 am

S3-05.  Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in NSABP trial B-31
Paik S, Pogue-Geile KL, Song N, Gavin PG, Kim S-R.  NSABP, Pittsburgh, PA.

 
     
10:45 am

S3-06.  Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
Hoadley KA, Barry WT, Pitcher BN, Parker JS, Wilkerson MD, Irvin, Jr W, Henry NL, Tolaney SM, Dang C, Krop IE, Berry DA, Mardis ER, Perou CM, Winer EP, Hudis CA, Carey LA.  The University of North Carolina, Chapel Hill, NC; Alliance Statistics and Data Center, Dana-Farber Cancer Institute, Boston, MA; Alliance Statistics and Data Center, Duke University, Durham, NC; Bon Secours Cancer Institute, Midlothian, VA; University of Michigan, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Alliance Statistics and Data Center, M.D. Anderson Cancer Center, Houston, TX; The Genome Institute, Washington University School of Medicine, St. Louis, MO.

 
     
11:00 am

S3-07.  16 year long-term follow-up of the IBIS-I breast cancer prevention trial
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF.  Centre for Cancer Prevention, Queen Mary University, London, United Kingdom; North Bristol NHS Trust, Bristol, United Kingdom; London Bridge Hospital, London, United Kingdom; Tampere University, Tampere, Finland; Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom; School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.

 
     
11:15 am

S3-08.  Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Analysis of the SOFT trial

Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos EM, Bellet M, Bonnefoi H, Climent MA, Pavesi L, Burstein HJ, Martino S, Davidson NE, Geyer, Jr CE, Walley BA, Coleman RE, Kerbrat P, Rabaglio-Poretti M, Coates AS, Goldhirsch A, Gelber RD.  SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group, Bern, Switzerland.

 
     
11:30 am

S3-09.  Patient-reported endocrine symptoms, sexual functioning and quality of life (QoL) in the IBCSG SOFT trial: Adjuvant treatment with tamoxifen (T) alone versus tamoxifen plus ovarian function suppression (OFS) in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC)

Ribi K, Luo W, Bernhard J, Francis PA, Bellet M, Burstein HJ, Pavesi L, Parmar V, Tondini C, Visini M, Torres R, Karlsson P, Spazzapan S, Avella A, Ruhstaller T, Puglisi F, Regan MM, Coates AS, Gelber RD, Fleming GF.  SOFT Investigators and International Breast Cancer Study Group, Bern, Switzerland.

 
     
11:45 am

S3-10.  Discussant

Hope S. Rugo, MD

University of California San Francisco

San Francisco, CA

 
     
12:00 pm - 1:00 pm LUNCH AND EXHIBITS  
     
1:00 pm - 2:00 pm

CASE DISCUSSION 1 – Ballroom A

 
  Moderator: Mothaffar Rimawi, MD, Baylor College of Medicine, Houston, TX  
     
1:00 pm - 2:00 pm BASIC SCIENCE FORUM - Ballroom B  
 

New Insights into Metastatic Progression

Moderator: Xiang Zhang, PhD, Baylor College of Medicine, Houston, TX

Collective invasion in breast cancer is led by specialized cancer cells with basal gene expression

Andrew Ewald, PhD

Johns Hopkins University School of Medicine

Baltimore, MD

Targeting the LIFR-Hippo-YAP pathway as an anti-metastatic strategy

Li Ma, PhD

UT MD Anderson Cancer Center

Houston, TX

 
     
2:15 pm - 2:45 pm AACR Distinguished Lectureship in Breast Cancer Research - Exhibit Hall D  
 

Genomic Analysis of Inherited Breast and Ovarian Cancer

Mary-Claire King, PhD

University of Washington

Seattle, WA

 
     
2:45 pm - 3:45 pm MINI-SYMPOSIUM 1 - Exhibit Hall D  
 

Breast Cancer Predisposition: Germline and Risk

Moderator: Laura J. van 't Veer, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

 
     
 

Characterising cancer risks for carriers of mutations in BRCA1, BRCA2, PALB2 and RAD51C genes

Antonis Antoniou

University of Cambridge

Cambridge, UNITED KINGDOM

 

Risk management of hereditary breast cancer

Banu Arun, MD

UT MD Anderson Cancer Center

Houston, TX

 
     
3:45 pm - 5:00 pm

GENERAL SESSION 4 – Exhibit Hall D

 
     
3:45 pm

S4-01. Macrophage-specific deletion of STAT5 disrupts normal mammary gland development and accelerates mammary tumorigenesis

Brady NJ, Farrar MA, Schwertfeger KL.  University of Minnesota, Minneapolis, MN.

 
     
4:00 pm

S4-02. Principles governing A-to-I RNA editing in breast cancer transcriptome

Fumagalli D, Gacquer D, Roth[eacute] F, Lefort A, Libert F, Brown DN, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart M, Abramowicz M, Campbell PJ, Detours V, Sotiriou C.  Jules Bordet Institute, Brussels, Belgium; Université Libre de Bruxelles (ULB), Brussels, Belgium; Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Dana-Farber Cancer Institute, Boston, MA; Hospital Erasme, Brussels, Belgium.

 
     
4:15 pm

S4-03. Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model
Albain KS, Zlobin AY, Covington KR, Gallahger BT, Hilsenbeck SG, Czerlanis CM, Lo S, Robinson PA, Gaynor ER, Godellas C, Bova D, Czaplicki K, Busby B, Stiff PJ, Fuqua SAW, Miele L, Osipo C.  Loyola University Chicago, Cardinal Bernardin Cancer Center, Maywood, IL; Baylor College of Medicine, Houston, TX; Louisiana State University, New Orleans, LA.

 
     
4:30 pm

S4-04. Predicting pre-surgical neoadjuvant chemotherapy response in breast cancer using diffuse optical spectroscopic imaging (DOSI): Results from the ACRIN 6691 study
Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter P, Mehta R, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman P, Yodh AG, Chung S-H, Schnall M, Snyder B, Hylton N, Boas DA, Carp SA, Isakoff SJ, Mankoff D.  University of California, Irvine, Irvine, CA; Brown University, Providence, RI; MD Anderson Cancer Center, Houston, TX; Dartmouth College, Hanover, NH; Boston University; MD Anderson Cancer Center; University of Pennsylvania; University of California, San Francisco; Massachusetts General Hospital.

 
     
4:45 pm

S4-05. Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Alliance)

Sikov WM, Barry WT, Hoadley KA, Pitcher BN, Singh B, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Berry DA, Hahn OM, Carey LA, Perou CM, Hudis CA, Winer EP.  Alpert Medical School of Brown University, Providence, RI; Alliance Statistics and Data Center, Dana-Farber Cancer Institute, Boston, MA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Alliance Statistics and Data Center, Durham, NC; New York University Medical Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA; Southeast Cancer Control Consortium, Winston-Salem, NC; Washington University-St. Louis Medical Center, St. Louis, MO; City of Hope Comprehensive Cancer Center, Duarte, CA; Mount Sinai Medical Center, New York, NY; Alliance Statistics and Data Center, MD Anderson Cancer Center, Houston, TX; University of Chicago Medical Center, Chicago, IL; Memorial Sloan Kettering Cancer Center, New York, NY.

 
     
5:00 pm - 7:00 pm

POSTER DISCUSSION 3: Intratumoral Heterogeneity – Ballroom A

 
     
 

Charles M. Perou, PhD - Co-Discussant

University of North Carolina at Chapel Hill

Chapel Hill, NC

and

TBA - Co-Discussant

 
     
5:00 pm - 7:00 pm

POSTER DISCUSSION 4: Late Effects of Cancer Therapies – Ballroom B

 
     
 

Dawn L. Hershman, MD - Chair and Co-Discussant

Columbia University Medical Center

New York, NY

and

Michelle Melisko, MD - Co-Discussant

University of California San Francisco

San Francisco, CA

 
     
5:00 pm - 7:00 pm POSTER SESSION 3 & reception – Exhibit Halls A-B  
     
 

Detection and Diagnosis

Breast Imaging - Mammography

Screening

Radiology - Tumor Monitoring

 

P3-01

P3-02

P3-03

     
 

Tumor Cell and Molecular Biology

Hormonal Factors and Receptors

Endocrine Therapy and Resistance

 

P3-04

P3-05

     
 

Prognostic and Predictive Factors

Response Predictions - Biomarkers and Other Factors

 

P3-06

     
 

Epidemiology, Risk, and Prevention

Epidemiology - Population Studies

Epidemiology - Genetic and Molecular

 

P3-07

P3-08

     
 

Treatment

Adjuvant Chemotherapy

Advanced Chemotherapy

Neoadjuvant Chemotherapy

Toxicities Management

Advanced Therapy - Other

 

P3-09

P3-10

P3-11

P3-12

P3-13

     
 

Ongoing Clinical Trials 2

Endocrine Therapies

Chemotherapies

New Drugs

Detection/Diagnosis

Metastases

 

OT2-1

OT2-2

OT2-3

OT2-4

OT2-5

     
7:30 pm - 9:30 pm

Open Satellite Event presented by Educational Concepts Group, LLC - Marriott Rivercenter

Metastatic Breast Cancer Beyond Progression: Tackling Later-Line Treatment Decisions

 
 
Tuesday | Wednesday | Friday | Saturday
 
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Presenter Instructions | Late Breaking | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright 2014 SABCS. All rights reserved. - Privacy Policy